Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study

SHR-1222 is a humanized monoclonal antibody targeting sclerostin and has the potential to promote bone formation and reduce bone resorption. This study was aimed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SHR-1222 in healthy men and postmenopausal w...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Zhijie, Fang, Pingfei, Yan, Xiang, Zhu, Ronghua, Feng, Qiong, Yan, Qiangyong, Yang, Lingfeng, Fan, Xiao, Xie, Yuting, Zhuang, Lihong, Feng, Sheng, Liu, Yantao, Zhong, Sheng, Yang, Zeyu, Sheng, Zhifeng, Zhou, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564351/
https://www.ncbi.nlm.nih.gov/pubmed/34744750
http://dx.doi.org/10.3389/fphar.2021.770073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564351/
https://www.ncbi.nlm.nih.gov/pubmed/34744750
http://dx.doi.org/10.3389/fphar.2021.770073

Ejemplares similares